First, the FDA has issued clearance for treatment energies up to 70 mJ, which makes the Fraxel laser the deepest fractional device on the market. The laser will be capable of creating superheated lesions in the tissue from 300 to 1400 microns deep into the skin. Reliant also introduced breakthrough ergonomic roller tips for the Fraxel SR1500, making the laser the first of its kind in the aesthetic market. The third announcement was introducing the second generation of the Fraxel Intelligent Optical Tracking system, which allows users to provide safe, effective, and predictable pattern delivery without the requirement of OptiGuide Blue contrast agent. FDA approval for advancements on Reliant lasers further supports the company's tradition of safe products with maximum clinical efficacy in the aesthetic industry. The Fraxel laser family has been widely accepted as the standard for laser skin treatment because of its safety and non-invasive technique in skin resurfacing. The Fraxel laser has been proven safe on all skin types and on all areas of the face and body. The FDA has approved Fraxel lasers to safely treat soft tissue coagulation, periorbital wrinkles, pigmented lesions, melasma, acne scars, surgical scars, and skin resurfacing.